New ambr 15 fermentation micro-scale bioreactor system provides enhanced microbial strain screening
New ambr 15 fermentation micro bioreactor system designed to enhance microbial strain screening applications.
The system offers parallel processing and walk-away control of 24 micro bioreactors.
Sartorius Stedim Biotech (SSB) has introduced the new ambr 15 fermentation system, an automated micro bioreactor system designed to enhance microbial strain screening with advanced capabilities supporting fed-batch microbial cultures.
The new system, based on the gold-standard ambr 15 micro bioreactor technology, has been designed to meet the requirements of microbial fermentation. It comprises 24 single-use stirred micro bioreactors (each with an 8–12 mL working volume) integrated to a user-friendly, automated workstation. The system offers parallel processing and walk-away control of 24 micro bioreactors, providing fermentation scientists with efficient, consistent results from an enhanced early stage screening platform.
ambr 15 fermentation has been designed to deliver high oxygen transfer rates, rapid pH and feed additions and is ideally suited for assessing the effects of different strains with microbial cultures. The ambr 15 fermentation measures pH and DO every 12 seconds and there are pumped liquid lines for base and feed addition in each micro bioreactor, enabling tight pH control and a semicontinuous feed supply. Additionally, the 10-mL working volume allows multiple samplings throughout the fermentation run to assess culture growth and protein production, thus providing more detailed process understanding.
The single-use micro bioreactor vessel contains an impeller suitable for fermentation and provides enhanced capability compared to shaking culture systems. The pH range of 6–8 is ideal for biopharm E. coli applications and cultures with similar requirements. As the ambr 15 vessels are single use and supplied sterile this eliminates cleaning and sterilization time, thus decreasing turnaround times between runs by many hours.
Dr Barney Zoro, ambr Product Manager at SSB explained: “Scientists have been trying to model microbial fermentation and screen microbial strains using shake plates and flasks but these devices are poor early-stage models as they are not able to achieve representative cell densities, and do not allow monitoring and control of pH or DO. With these issues in mind, we developed ambr 15 fermentation and have data showing system consistency, repeatability and predictive selection of strains. This demonstrates that the system is an excellent tool for enhanced screening applications and we are confident that fermentation scientists will significantly reduce their time and resource demands when performing enhanced microbial strain selection studies using an ambr 15 fermentation system.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...